Renal injury induced by long-term administration of cyclosporin A to rats
- PMID: 3591904
- PMCID: PMC1899773
Renal injury induced by long-term administration of cyclosporin A to rats
Abstract
Chronic administration of cyclosporin A (CyA) to animals and humans results in renal damage characterized by tubulointerstitial lesions and renal insufficiency. This nephrotoxicity limits the use of CyA in the management of graft rejection. Despite recent investigations in this area, relatively few studies correlate structural and functional abnormalities in animals undergoing long-term CyA treatment. The authors therefore treated 30 rats with CyA at the dose of 40 mg/kg/48 hr for up to 5 months. An additional group of 30 rats was given the vehicle alone and was considered as a control group. Renal morphology and function were studied. For evaluation of the effect of drug withdrawal, a third group of 25 animals received CyA for 3 months and was followed for another 2 additional months after drug withdrawal. The results show that the chronic administration of CyA to rats induced complex renal morphologic changes, associated with renal insufficiency, polyuria, and enhanced sodium excretion. Withdrawal of the drug resulted in almost complete normalization of morphologic and functional parameters. The early morphologic expression of CyA nephrotoxicity was isometric vacuolization and loss of brush border involving the proximal tubular cells, followed by a peculiar lesion in distal tubular cells due to glycogen accumulation. Glomerular and interstitial damage was mild and appeared only after 3 months of CyA administration. No vascular abnormalities were found in rats treated with CyA for 5 months. A CyA-induced decrease in the glomerular filtration rate (GFR) correlates with brush border loss but not with isometric vacuolization. The distal tubular glycogen accumulation was associated with the development of polyuria and enhanced sodium excretion. Given the high blood sugar level and severe glycosuria in animals treated chronically with CyA, it is also concluded that CyA possesses a diabetogenic effect which is likely to be responsible for glycogen accumulation at the tubular level.
Similar articles
-
Renal vascular and thrombotic effects of cyclosporine.Am J Kidney Dis. 1989 Apr;13(4):261-72. doi: 10.1016/s0272-6386(89)80032-0. Am J Kidney Dis. 1989. PMID: 2650537 Review.
-
Nephrotoxicity of cyclosporin A. A lithium clearance and micropuncture study in rats.Eur J Clin Invest. 1986 Feb;16(1):69-77. doi: 10.1111/j.1365-2362.1986.tb01310.x. Eur J Clin Invest. 1986. PMID: 3084276
-
Thromboxane receptor blockade attenuates the toxic effect of cyclosporine in experimental renal transplantation.Circulation. 1990 Jan;81(1 Suppl):I61-7; discussion I68. Circulation. 1990. PMID: 2136819
-
Long-term cyclosporin A nephrotoxicity in the rat. Evaluation of a morphological scoring system and of co-treatment with isradipine.APMIS. 1994 May;102(5):347-55. APMIS. 1994. PMID: 8024736
-
Renal dysfunction in animal models of cyclosporine toxicity.Transplant Proc. 1985 Aug;17(4 Suppl 1):155-9. Transplant Proc. 1985. PMID: 3895656 Review. No abstract available.
Cited by
-
Complications of nephrotic syndrome.Korean J Pediatr. 2011 Aug;54(8):322-8. doi: 10.3345/kjp.2011.54.8.322. Epub 2011 Aug 31. Korean J Pediatr. 2011. PMID: 22087198 Free PMC article.
-
Expression of ammonia transporters, Rhbg and Rhcg, in chronic cyclosporine nephropathy in rats.Nephron Exp Nephrol. 2008;110(2):e49-58. doi: 10.1159/000153245. Epub 2008 Sep 8. Nephron Exp Nephrol. 2008. PMID: 18776723 Free PMC article.
-
Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.Drug Saf. 1999 Dec;21(6):471-88. doi: 10.2165/00002018-199921060-00004. Drug Saf. 1999. PMID: 10612271 Review.
-
Endocrine and metabolic abnormalities following kidney transplantation.Klin Wochenschr. 1989 Sep 1;67(17):907-18. doi: 10.1007/BF01717348. Klin Wochenschr. 1989. PMID: 2681969 Review.
-
Difference between aortic and renal vascular reactivity in cyclosporin A treated rats and the effect of cicletanine.Naunyn Schmiedebergs Arch Pharmacol. 1992 Mar;345(3):356-61. doi: 10.1007/BF00168698. Naunyn Schmiedebergs Arch Pharmacol. 1992. PMID: 1620237
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical